Shares of Veru (NASDAQ:VERU) rose 7% in pre-market trading after the company reported Q2 results.
Earnings per share rose 83.33% over the past year to ($0.01), which beat the estimate of ($0.04).
Revenue of $9,943,000 rose by 42.53% year over year, which missed the estimate of $10,970,000.
Veru hasn't issued any earnings guidance for the time being.
Veru hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 13, 2020
Time: 06:49 PM ET
52-week high: $4.74
52-week low: $1.50
Price action over last quarter: down 16.05%
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.